Cytokinetics (NASDAQ:CYTK) Shares Gap Down - Should You Sell?

Key Points

• Cytokinetics shares fell sharply, opening at $73.88 after closing at $77.90 and last trading near $73.03.
• Analyst sentiment remains broadly positive: 19 analysts rate the stock a Buy, one rates it Hold, and one rates it Sell. The consensus rating is “Moderate Buy,” with a target price of $102.20.
• The company exceeded quarterly loss and revenue estimates, reporting an adjusted loss of $1.50 per share versus expectations of $1.63 and revenue of $28.62 million, though revenue declined 57.1% year over year. Insiders have sold about $8.8 million of shares over the past 90 days.

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $77.90, but opened at $73.88. Cytokinetics shares last traded at $73.03, with a volume of 603,315 shares changing hands.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Needham & Company LLC upped their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the company a "buy" rating in a report on Friday, August 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Cytokinetics in a research report on Friday, July 17th. HC Wainwright restated a "buy" rating on shares of Cytokinetics in a research note on Friday, August 14th. JPMorgan Chase & Co. lifted their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Finally, Truist Financial upped their price target on shares of Cytokinetics from $106.00 to $112.00 and gave the company a "buy" rating in a research note on Monday, August 10th. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $102.20.

Cytokinetics Stock Performance

The stock has a market capitalization of $9.10 billion, a price-to-earnings ratio of -10.12 and a beta of 0.38. The business has a fifty day simple moving average of $80.25 and a 200 day simple moving average of $72.23.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping analysts' consensus estimates of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. The firm's quarterly revenue was down 57.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.12) EPS. On average, sell-side analysts forecast that Cytokinetics, Incorporated will post -6 earnings per share for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In other news, EVP Sung Lee sold 1,112 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $87.79, for a total transaction of $97,622.48. Following the transaction, the executive vice president directly owned 63,221 shares of the company's stock, valued at approximately $5,550,171.59. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $76.76, for a total transaction of $575,700.00. Following the completion of the sale, the chief executive officer owned 377,820 shares of the company's stock, valued at approximately $29,001,463.20. The trade was a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 111,179 shares of company stock worth $8,803,649. 2.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors have recently made changes to their positions in CYTK. Vanguard Group Inc. grew its holdings in shares of Cytokinetics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company's stock worth $765,538,000 after purchasing an additional 191,336 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Cytokinetics by 63.8% in the second quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company's stock worth $34,502,000 after purchasing an additional 157,700 shares during the period. Royce & Associates LP raised its stake in Cytokinetics by 44.3% in the fourth quarter. Royce & Associates LP now owns 144,426 shares of the biopharmaceutical company's stock valued at $9,177,000 after purchasing an additional 44,343 shares in the last quarter. Norges Bank acquired a new position in Cytokinetics in the fourth quarter valued at about $51,281,000. Finally, Siren L.L.C. bought a new stake in Cytokinetics during the first quarter worth about $40,466,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source